Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| Immunostimulants drugs | 80 | 0.86 [0.74; 1.01], 12 RCTs, I2=0% demonstrated
inconclusive result | 1.11 [1.00; 1.24], 20 RCTs, I2=35% demonstrated
inconclusive result | 0.89 [0.80; 0.98], 70 RCTs, I2=27% demonstrated
moderate degree of certainty | 3.02 [1.30; 7.02], 9 RCTs, I2=83%
moderate degree of certainty | |
| Immunosuppressants drugs | 69 | 0.70 [0.51; 0.96], 11 RCTs, I2=59% demonstrated
moderate degree of certainty | 1.25 [1.13; 1.38], 14 RCTs, I2=15% demonstrated
high degree of certainty | 0.77 [0.69; 0.86], 44 RCTs, I2=22% demonstrated
safety concern
inconclusive result | - | |
| anti-inflammatory therapies | 26 | 0.18 [0.05; 0.57], 4 RCTs, I2=14%
moderate degree of certainty | 10.27 [1.17; 90.18], 1 RCT, I2=0%
unassessable degree of certainty | 0.99 [0.94; 1.05], 12 RCTs, I2=0%
inconclusive result | 1.71 [0.80; 3.64], 1 RCT, I2=0%
inconclusive result | |
| corticosteroids | 22 | 0.67 [0.44; 1.03], 2 RCTs, I2=0%
inconclusive result | 1.44 [0.89; 2.33], 4 RCTs, I2=65%
inconclusive result | 0.85 [0.73; 0.99], 15 RCTs, I2=64% demonstrated
moderate degree of certainty | 1.78 [1.06; 3.00], 1 RCT, I2=0%
unassessable degree of certainty | |
| Kinase inhibitors | 3 | - | - | - | - | |
| leflunomide | 1 | 1.00 [0.02; 52.54], 1 RCT, I2=0%
inconclusive result | - | 1.00 [0.02; 52.54], 1 RCT, I2=0%
inconclusive result | - | |
| Apilimod | 0 | - | - | - | - | |
| inhaled corticosteroids | 0 | - | - | - | - | |
| meplazumab | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| statins | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
